Literature DB >> 17592070

Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma.

Gian Paolo Rossi1, Anna Belfiore, Giampaolo Bernini, Giovambattista Desideri, Bruno Fabris, Claudio Ferri, Gilberta Giacchetti, Claudio Letizia, Mauro Maccario, Francesca Mallamaci, Massimo Mannelli, Gaetana Palumbo, Damiano Rizzoni, Ermanno Rossi, Enrico Agabiti-Rosei, Achille C Pessina, Franco Mantero.   

Abstract

We performed a prospective head-to-head comparison of the accuracy of the captopril test (CAPT) and the saline infusion test (SAL) for confirming primary aldosteronism due to an aldosterone-producing adenoma (APA) in patients with different sodium intake. A total of 317 (26.9%) of the 1125 patients screened in the Primary Aldosteronism Prevalence in Italy Study underwent both CAPT and SAL. They were composed of the patients with a high aldosterone/renin ratio baseline and 1 every 4 patients without such criterion. The accuracy of post-CAPT or post-SAL plasma aldosterone values for diagnosing APA was estimated with the area under the receiver operator characteristics curves. Primary aldosteronism was found in 120 patients, of which 46 had an APA. No untoward effect occurred with either test. The area under the receiver operator characteristics curve of plasma aldosterone for both tests was higher (P<0.0001) than that under the diagonal, but the between-test difference was borderline significant (P=0.054). The optimal aldosterone cutoff value for identifying APA was 13.9 and 6.75 ng/dL for the CAPT and SAL, respectively. Even at these cutoffs, sensitivity and specificity were moderate because of overlap of values between patients with and without APA. When examined in relation to sodium intake, the accuracy of the SAL surpassed that of the CAPT in the patients with a sodium intake <or=130 mEq per day; this difference waned at a higher Na(+) intake. Thus, both the CAPT and the SAL are safe and moderately accurate for excluding APA; at a sodium intake >7.6 g per day, the SAL offers no advantage over the easier-to-perform CAPT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592070     DOI: 10.1161/HYPERTENSIONAHA.107.091827

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

Review 1.  Diagnosis and treatment of primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Franco Veglio
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

2.  A diagnostic algorithm--the holy grail of primary aldosteronism.

Authors:  Gian Paolo Rossi; Teresa Maria Seccia; Achille C Pessina
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

3.  Shortened saline infusion test for subtype prediction in primary aldosteronism.

Authors:  Kazutaka Nanba; Mika Tsuiki; Hironobu Umakoshi; Aya Nanba; Yuusuke Hirokawa; Takeshi Usui; Tetsuya Tagami; Akira Shimatsu; Tomoko Suzuki; Akiyo Tanabe; Mitsuhide Naruse
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

4.  Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism.

Authors:  M Tagawa; M Ghosn; H Wachtel; D Fraker; R R Townsend; S Trerotola; D L Cohen
Journal:  J Hum Hypertens       Date:  2017-01-12       Impact factor: 3.012

5.  Potential effects of age on screening for primary aldosteronism.

Authors:  Q Luo; N F Li; X G Yao; D L Zhang; S F Y Abulikemu; G J Chang; K M Zhou; G L Wang; M H Wang; W J Ouyang; Q Y Cheng; Y Jia
Journal:  J Hum Hypertens       Date:  2015-04-16       Impact factor: 3.012

6.  [Two case reports on resistant hypertension].

Authors:  C Beger; H Haller; F P Limbourg
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

Review 7.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

8.  Fully automated chemiluminescence vs RIA aldosterone assay in primary aldosteronism work-up.

Authors:  F Pizzolo; G Salvagno; B Caruso; C Cocco; F Zorzi; C Zaltron; A Castagna; L Bertolone; F Morandini; G Lippi; O Olivieri
Journal:  J Hum Hypertens       Date:  2017-08-24       Impact factor: 3.012

Review 9.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 10.  Progress in primary aldosteronism: present challenges and perspectives.

Authors:  C E Gomez-Sanchez; G P Rossi; F Fallo; M Mannelli
Journal:  Horm Metab Res       Date:  2010-01-20       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.